VIB is a research institute located in Flanders, Belgium. VIB was founded by the Flemish government in 1995, and became a full-fledged institute on 1 January 1996
The Latest Bing News on:
Flanders Institute of Biotechnology (VIB) Research
- New Iberia Research Center breaks ground on biotech lab expansion
The New Iberia Research Center celebrated a major expansion of its biotech field. Officials broke ground on the new expansion on Friday, April 26.
- Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors
Flindr Therapeutics B.V. ("Flindr" or "the Company"), a precision oncology therapeutics company, today announces a €20 million Series A financing to advance its pipeline of first-in-class, small ...
- Remarkable Findings – New Research Reveals That the Spinal Cord Can Learn and Memorize
New research reveals that spinal cord neurons possess the capability to learn and retain information independently of the brain. The spinal cord is often described as merely a conduit for transmitting ...
- New mechanism uncovered in early stages of Alzheimer's disease
The mechanism behind this remained a mystery until now. In their latest study, the lab of Annaert at the VIB-KU Leuven Center for Brain & Disease Research identified a mechanism explaining how APP may ...
The Latest Bing News on:
Flanders Institute of Biotechnology (VIB) Discovery
- Franklin Biotechnology Discovery Fund;Advisor
Under normal market conditions, the Fund predominantly invests in equity securities and invests at least 80% of its net assets in securities of biotechnology companies(at least 50% of its earnings ...
- Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors
The Company utilizes the "ImmunoGram Drug Discovery Engine", which ... a research collaboration with the NKI, and the VIB (Flanders Institute of Biotechnology). About V-Bio Ventures V-Bio Ventures ...
- Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors
Flindr Therapeutics B.V. ("Flindr" or "the Company"), a precision oncology therapeutics company, today announces a €20 million Series A financing to advance its pipeline of first-in-class, small ...
- New mechanism uncovered in early stages of Alzheimer's disease
In their latest study, the lab of Annaert at the VIB-KU Leuven Center for Brain & Disease Research identified a mechanism explaining how APP may contribute to these early stages of AD. This discovery ...
- Discovery of the first fractal molecule in nature
An international team of researchers led by groups from the Max Planck Institute in Marburg and the Philipps University in Marburg has stumbled upon the first regular molecular fractal in nature.
